Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 7584 results found since Jan 2013.
Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis
This study aimed to explore the ability of ivermectin (0.6 mg/kg) to alleviate bleomycin-induced biochemical derangements and histological changes in an experimental PF rat model. This can provide the means to validate the clinical utility of ivermectin as a treatment option for idiopathic PF. The results showed that ivermectin mitigated the bleomycin-evoked pulmonary injury, as manifested by the reduced infiltration of inflammatory cells, as well as decreased the inflammation and fibrosis scores. Intriguingly, ivermectin decreased collagen fiber deposition and suppressed transforming growth factor-β1 (TGF-β1) and ...
Source: J Zhejiang Univ Sci ... - August 8, 2023 Category: Science Authors: Mai A Abd-Elmawla Heba R Ghaiad Enas S Gad Kawkab A Ahmed Maha Abdelmonem Source Type: research
